Serum therapy revisited: animal models of infection and development of passive antibody therapy

Continuous cultures of fused cells secreting antibody of predefined specificity

Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200

The principles and practice of medicine

(1938) · The American Journal of Surgery · doi:10.1016/s0002-9610(38)91188-2 · Cited by 1,657

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

LoBuglio, A. F., Wheeler, R. H., Trang, J. M., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524

Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.

Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS

Flexner, S. (1913) · The Journal of Experimental Medicine · doi:10.1084/jem.17.5.553 · Cited by 175

THE FURTHER SEPARATION OF TYPES AMONG THE PNEUMOCOCCI HITHERTO INCLUDED IN GROUP IV AND THE DEVELOPMENT OF THERAPEUTIC ANTISERA FOR THESE TYPES

Cooper, G. M., Rosenstein, C., Walter, A. W., & Peizer, L. R. (1932) · The Journal of Experimental Medicine · doi:10.1084/jem.55.4.531 · Cited by 96

SEROLOGICAL RELATIONSHIPS AMONG MENINGOCOCCI

Branham, S. E. (1953) · Bacteriological Reviews · doi:10.1128/br.17.3.175-188.1953 · Cited by 84

In Vitro Antibodies: Strategies for Production and Application

Morrison, S. L. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.001323 · Cited by 83

Experimental Meningococcal Infection in Mice

Miller, C. P. (1933) · Science · doi:10.1126/science.78.2024.340 · Cited by 77

A BIOLOGIC CLASSIFICATION OF PNEUMOCOCCI BY MEANS OF IMMUNITY REACTIONS

Dochez, A. R. (1913) · JAMA · doi:10.1001/jama.1913.04350100005003 · Cited by 74

The therapeutics, based on virus specific antibodies, for special prophylactic and current of COVID-19

Sizikova, T. E., Lebedinskaya, E. V., Lebedev, V. N., & Borisevich, S. V. (2021) · Infectious diseases News Opinions Training · doi:10.33029/2305-3496-2021-10-4-98-104 · Cited by 1

Models for Inducing Experimental Cryptococcosis in Mice

Castro-Lopez, N., & Wormley, F. L. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3722-7_3 · Cited by 1

The Logic and History of Passive Immunity and Antibody Therapies

Casadevall, A., & Paneth, N. (2024) · Current topics in microbiology and immunology · doi:10.1007/82_2024_267 · Cited by 1

From antibodies to nanobodies: The next frontier in cancer theranostics for solid tumors

Mehrotra, S., Kaur, N., Kaur, S., Matharoo, K., & Pandey, R. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.014 · Cited by 1

Pneumococcal Infections

Pelton, S. I., Yildirim, I. B., Olarte, L., & Hultén, K. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00085-6 · Cited by 1

In silico site-directed mutagenesis of neutralizing mAb 4C4 and analysis of its interaction with G-H loop of VP1 to explore its therapeutic applications against FMD

Sahu, T. K., Pradhan, D., Rao, A. R., & Jena, L. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1494631 · Cited by 1

COVID-19: Pathogenesis and Pharmacological Basis for Use of Passive Antibody Therapy

Ojha, S., Chadha, H., & Mahor, S. (2020) · Current Drug Therapy · doi:10.2174/1574885515999200813193747 · Cited by 1

Anticuerpos monoclonales: aplicaciones en infectología

Medina, C. (2021) · Diagnóstico · doi:10.33734/diagnostico.v60i4.332 · Cited by 1

Autologous serum skin test: anin vivoprozone-like phenomenon?

Pavlović, M. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03274.x · Cited by 1

Elucidating the Role of the Humoral Response in Mycobacterium tuberculosis infected Cynomolgus Macaques

Phuah, J. Y. (2013) · D-Scholarship@Pitt (University of Pittsburgh)

Acquired Humoral Immunity toCryptococcus neoformans

Pirofski, L., & Casadevall, A. (2014) · ASM Press eBooks · doi:10.1128/9781555816858.ch28

Estudo de marcação do anticorpo monoclonal anti-PBP2a com 99mTc

Mororó, J. D. S. (2012) · doi:10.11606/d.85.2012.tde-06032013-151412

Construção de uma bibilioteca de anticorpos ScFv dirigidos contra o fator de crescimento vascular (VEGF)

Gomes, C. H. R. (2013) · doi:10.11606/d.46.2013.tde-09082013-093807

Human Monoclonal Antibodies Against HIV and Emerging Viruses

Dimitrov, D. S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-569-5_34

Local application of human IgG to prevent biomaterial-centered bacterial infection

Poelstra, K. A. (2000) · University of Groningen research database (University of Groningen / Centre for Information Technology)

Adjunctive Therapies in Severe Community-Acquired Pneumonia

Skerrett, S. J. (2001) · Perspectives on critical care infectious diseases · doi:10.1007/978-1-4615-1631-6_10

Antibody-Mediated Immunity to Fungi in the Lungs

Feldmesser, M., & Casadevall, A. (2005) · Springer eBooks · doi:10.1007/0-387-25445-5_9

Les immunoglobulines en thérapeutique anti-infectieuse

Berthelot, P., Guglielminotti, C., Fresard, A., Zéni, F., & Lucht, F. (1998) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(98)80121-2

Produção e purificação de anticorpos específicos contra Staphylococcus aureus resistente à meticilina produzidos em eqüinos imunizados com uma vacina de DNA

dos Santos, D. V. (2006) · Americanae (AECID Library)

Passive antibody therapy revisited in light of the increasing antibiotic resistance: serum prepared within a farm reduces mortality of dystrophic neonate piglets.

Normantienė, T., Žukaitė, V., & Biziulevičius, G. A. (2000) · Revue Méd Vét

Contributions of pneumococcal virulence factors to secondary Streptococcus pneumoniae infection following influenza infection

King, Q. O. (2009) · Montana State University ScholarWorks (Montana State University)

GUEST COMMENTARY Antibody-Mediated Immunity against Intracellular Pathogens: Two-Dimensional Thinking Comes Full Circle

Casadevall, A. (2003)

Assessment of natural and outer membrane vesicle (OMV) vaccine induced immunity against Neisseria meningitidis serogroup B in an infant rat infection model

Toropainen, M. (2005) · Työväentutkimus Vuosikirja

Different Receptors through Cryptococcus neoformans Variants Promote Phagocytosis of Murine IgG1 and IgG3 Isotype Switch

Saylor, C., & Dadachova, E. (2010)

Thecaseforpathogen-specific therapy

Casadevall, A. (2009)

The immune response to streptococcus pneumoniae and pneumococcal polysaccharides

Rabquer, B. J. (2006) · OhioLink ETD Center (Ohio Library and Information Network)

Characterisation of new potential vaccine candidates against infections caused by Staphylococcus aureus

Tosetti, B. (2010) · Kölner Universitäts PublikationsServer (Universität zu Köln)

Natural adaptive immunity to Streptococcus pneumoniae lung infection

Wilson, R. (2014) · UCL Discovery (University College London)

Obtenção de anticorpos monoclonais humanos antitetânicos.

Aliprandini, E. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.87.2015.tde-04122015-141425

Do Veterinary Paraprofessionals Provide Quality Clinical Veterinary Services for Cattle? Results from a Role Play Experiment in Rural UgandaPreprint

Ilukor, J., & Regina Birner, B. (2015) · RePEc: Research Papers in Economics · doi:10.22004/ag.econ.211781

Monoclonal Antibodies for Infectious Diseases

Projan, S. J. (2016) · doi:10.1002/9781118940648.ch9

Untersuchungen zur therapeutischen Wirksamkeit von felinen Antikörpern gegen Parvoviren bei Hunden mit Parvovirose

Gerlach, M. (2017) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.21265

Desenvolvimento de novos vetores para a produção de bibliotecas de anticorpos pelo sistema do phage display

Gomes, C. H. R. (2019) · doi:10.11606/t.46.2019.tde-22032019-152757

Plasma Therapy in the fight against Sars-CoV-2: what boils in the pot.Preprint

Vitiello, A., Ferrara, F., Porta, R. L., & Pelliccia, C. (2020) · doi:10.22541/au.158920590.02731156

Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy

Hoda, F., Verma, R., Rastogi, S., Iqubal, A., Haque, S. E., Akhtar, M., & Najmi, A. K. (2020) · Coronaviruses · doi:10.2174/2666796701999201014160857

Convalescent plasma therapy for COVID-19: a review of old therapy against new disease

Chapagain, U., Raunair, G. P., Chapagain, K., & Verma, R. K. (2020) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20205133

A Step Toward Optimizing Regenerative Medicine Principle to Combat COVID-19

Sharma, S., Jeyaraman, M., Muthu, S., Anudeep, T. C., Jeyaraman, N., Satish, A. S., Kumar, V., Somasundaram, R., Jain, R., & Jha, S. K. (2021) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0041-1731597

A importância do plasma convalescente e/ou globulina hiperimune em pacientes com doença coronavírus 2019 (Covid-19) / The importance of convalescent plasma and/or hyperimmune globulin in patients with coronavirus disease 2019 (Covid-19)

Souza, E. L. D., da Silva, W. T., Alves, L. S. D. G., Marçal, F. A., Perez, A. A. G., Andrade, G. M., Tovar, R. C., & Azevedo, J. L. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n5-344

Streptococcus-Pneumoniae Diseases

Schmitt, H., & Hrynkevych, K. (2021) · doi:10.33442/vt202133

Innate Immune-mediated Antiviral Response to SARS-CoV-2 and Convalescent sera a potential Prophylactic and Therapeutic Agent to Tackle COVID-19 (Preprint)Preprint

Abdullah, A., & Faisal, S. (2020) · doi:10.2196/preprints.21091

IMMUNOMODULATING AGENTS

Pine, T. R. L., & Hill, H. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50259-4

Antibodies

Lopez-Ribot, J. L., Diez‐Orejas, R., & Gil, C. (2007) · Springer eBooks · doi:10.1007/1-4020-5492-0_10

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)

Santis, G. C. D., & Calado, R. T. (2022) · Emerging infectious diseases · doi:10.3201/eid2805.220363

Review on Antibody as A Drug of Choice

(2017) · Archives on Veterinary Science and Technology · doi:10.29011/2637-9988.100012

Emerging Treatment Regimens In Pharmaceutics During Post Covid-19 Epidemic

Chandra, K. (2023) · NeuroQuantology · doi:10.48047/nq.2022.20.4.nq22354

Antibody Therapy as Alternative to Antibiotics

Lama, M. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123975123010005

Passive Immunization

Slifka, M. K., & Amanna, I. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00009-8

Preclinical Development of Monoclonal Antibodies

Meyer-Tamaki, K. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00005-0

Immunomodulating Agents

Furst, L. E., Hill, H. R., & Lapine, T. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00258-2

Fungal Vaccines: Recent Trends

Shahid, M., Malik, A., Jahan, N., AL-Mohammed, H. I., Al‐Sultan, A. I., & Aboulmagd, E. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_18

Conception et caractérisation d'anticorps non immunogènes : application à un anticorps anti-Salmonelles/Shigelles

Sierocki, R. (2020) · theses.fr (ABES) · doi:10.70675/a21eef57z41b9z4748z9da6z2af2b38799d6

Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother

Casadevall, A., Scharff, M. D., Casadevalll, A., Matthew, & Scharff, D. (1994)

MINIREVIEW SerumTherapy Revisited: AnimalModels ofInfection and Development ofPassive Antibody Therapy

Scharff, M. D. (1994)

PEARLS The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases

Casadevall, A., & Pirofski, L.-A. (2016)

Back to the future: Antibody-based strategies for the treatment of infectious diseases

Oral, H. B., Özakın, C., & Akdiş, C. A. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:3:225 · Cited by 19

The Development of Serum Therapy.

McCLINTOCK, C. T. (1898) · PubMed Central